

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  28D0454924	<b>(X3) Date Survey Completed</b>  07/08/2021
<b>Name of Provider or Supplier</b>  York General Health Care Services	<b>Street Address, City, State</b>  2222 North Lincoln Avenue, York, NE	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2000</b>	<p><b>ENROLLMENT AND TESTING OF SAMPLES</b> CFR(s): 493.801</p> <p>Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994.</p> <p>This CONDITION is not met as evidenced by: Based on review of the laboratory's list of tests performed, review of 2020 proficiency testing, and interview with general supervisor the laboratory failed to enroll in an approved proficiency testing program for moderate complexity Human Chorionic Gonadotropin (HCG), quantitative serum. Findings are: 1. Review of the laboratory's list of tests performed revealed the laboratory had a yearly volume of twenty-sixty moderate complexity Human Chorionic Gonadotropin (HCG), quantitative serum tests for 2020. 2. Review of the laboratory's 2020 proficiency testing revealed the laboratory failed to enroll in an approved program for moderate complexity Human Chorionic Gonadotropin (HCG), quantitative serum. 3. Interview with general supervisor on 7/8/2021 at 11:04 AM confirmed the laboratory had not enrolled in an approved program for moderate complexity Human Chorionic Gonadotropin (HCG), quantitative serum for 2020.</p>